Guided Therapeutics (GTHP) Free Cash Flow Growth (1y) (2012 - 2025)
Guided Therapeutics (GTHP) Free Cash Flow Growth (1y) (2012 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.61 Bn | 175.32 Bn | 6.27 Bn | -1.82% |
| 2 | Stryker | 128.95 Bn | 126.07 Bn | 3.81 Bn | 226.77% |
| 3 | Medtronic | 108.22 Bn | 99.00 Bn | 6.41 Bn | 0.77% |
| 4 | Boston Scientific | 68.29 Bn | 66.84 Bn | 3.61 Bn | -51.69% |
| 5 | Edwards Lifesciences | 48.30 Bn | 44.63 Bn | 1.29 Bn | -109.40% |
| 6 | Dexcom | 28.31 Bn | 27.19 Bn | 750.30 Mn | 363.84% |
| 7 | GE HealthCare Technologies | 28.03 Bn | 25.75 Bn | 1.98 Bn | -31.71% |
| 8 | Smith & Nephew | 27.01 Bn | 26.43 Bn | - | - |
| 9 | Koninklijke Philips | 24.04 Bn | 20.91 Bn | 2.07 Bn | 133.09% |
| 10 | Guided Therapeutics | 20.78 Mn | 20.72 Mn | 458,000.00 | 12.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 12.35% |
| Sep 30, 2025 | 41.44% |
| Jun 30, 2025 | 21.03% |
| Mar 31, 2025 | -231.00% |
| Dec 31, 2024 | 1.19% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | 51.14% |
| Mar 31, 2024 | 79.96% |
| Dec 31, 2023 | 1.75% |
| Sep 30, 2023 | 22.33% |
| Jun 30, 2023 | -19.67% |
| Mar 31, 2023 | -158.55% |
| Dec 31, 2022 | -367.19% |
| Sep 30, 2022 | 15.06% |
| Jun 30, 2022 | 47.41% |
| Mar 31, 2022 | 39.88% |
| Dec 31, 2021 | 138.67% |
| Sep 30, 2021 | -21.73% |
| Jun 30, 2021 | -63.38% |
| Mar 31, 2021 | 39.43% |